Stay updated with the latest autoimmune-disease news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on autoimmune-disease topics.
New Delhi [India], April 3 (ANI): US President Donald Trump's decision to impose a 100 per cent tariff on patented pharmaceutical imports--citing national security and supply chain risks following a Section 232 probe--is expected to have a mixed impact on India. Crucially for India, the proclamation clarifies that generic drugs--a segment in which Indian firms dominate globally--are exempt "at this time," adding that such products "shall not be subject to Section 232 tariffs." For India, the i ...Read More >
New Delhi [India], April 3 (ANI): US President Donald Trump's decision to impose a 100 per cent tariff on patented pharmaceutical imports--citing national security and supply chain risks following a Section 232 probe--is expected to have a mixed impact on India. Crucially for India, the proclamation clarifies that generic drugs--a segment in which Indian firms dominate globally--are exempt "at this time," adding that such products "shall not be subject to Section 232 tariffs." Also Read | Delh ...Read More >
Mumbai, Oct 31 (SocialNews.XYZ) Actress Deepika Padukone, who has been a strong advocate for mental health awareness, reacted to cricketer Jemimah Rodrigues' recent revelation about battling anxiety. The 'Om Shanti Om' actress, known for openly sharing her own struggles with depression in the past, praised Jemimah for her honesty and courage in speaking up, highlighting the importance of conversations around mental well-being in sports and beyond. Taking to her Instagram Stories, Deepika Paduko ...Read More >
New Delhi [India], October 31 (ANI): The U.S. Food and Drug Administration (FDA) has announced major steps to make it faster and less costly to develop biosimilar medicines, lower-cost "generic" alternatives to biologic drugs used to treat serious and chronic diseases. In a new draft guidance, the FDA has proposed major updates aimed at simplifying biosimilarity studies and reducing unnecessary clinical testing. The agency also launched a separate initiative to make it easier for biosimilars t ...Read More >
(Reuters) -Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion. The collaborations aim to increase the availability of Lilly's key drugs, including those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions, the company said. "We are making significant investments to increase manufactu ...Read More >
Mumbai: Shares of Glenmark Pharmaceuticals rallied as much as 20% and made a fresh lifetime high on Friday after it announced an exclusive licensing deal between Ichnos Glenmark Innovation (IGI) and AbbVie to develop and commercialise IGI's drug used for oncology and autoimmune diseases. The stock ended at ₹2,175.0 on Friday, up 14.3%. It made a record high of ₹2,284.8 during the day. "The deal marks a turning point for Glenmark and could lead to significant re-rating of the stock," said Ariji ...Read More >
New Delhi, Jul 11 (PTI) Shares of Glenmark Pharmaceuticals Ltd on Friday jumped 10 per cent after the firm said it has signed a deal with AbbVie to commmercialise its underdevelopment drug aimed to treat cancer and autoimmune diseases in an up to USD 2 billion deal, one of the largest transactions in the pharma sector. The stock surged 9.99 per cent to hit its 52-week high as well as the upper circuit limit of Rs 2,095.65 on the BSE. At the NSE, the stock zoomed 10 per cent to Rs 2,094.40 -- i ...Read More >
New Delhi, Jul 10 (PTI) Glenmark Pharmaceuticals Ltd on Thursday said its arm Ichnos Glenmark Innovation, Inc has signed a licensing agreement with AbbVie for commercialisation of its lead investigational asset 'ISB 2001' targeted for treatment of cancer and autoimmune diseases. ISB 2001 has been developed using Ichnos Glenmark Innovation's (IGI) proprietary 'BEAT protein platform' for oncology and autoimmune diseases, Glenmark Pharmaceuticals said in a regulatory filing. Also Read | Bodoland ...Read More >
New Delhi, Jul 10 (PTI) Glenmark Pharmaceuticals Ltd on Thursday said its arm Ichnos Glenmark Innovation, Inc has signed a licensing agreement with AbbVie for commercialisation of its lead investigational asset 'ISB 2001' targeted for treatment of cancer and autoimmune diseases. ISB 2001 has been developed using Ichnos Glenmark Innovation's (IGI) proprietary 'BEAT protein platform' for oncology and autoimmune diseases, Glenmark Pharmaceuticals said in a regulatory filing. Under the agreement, ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.